This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Landmark Study Of More Than 27,000 Women Shows Favorable Results Of Roche's CINtec PLUS Cytology Test

Stocks in this article: ROG

TUCSON, Ariz., Nov. 4, 2013 /PRNewswire/ --  Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, is pleased to announce the positive findings of the Primary ASC-US LSIL Marker Study (PALMS) that have been published in The Journal of the National Cancer Institute. 1 The pan-European study, including more than 27,000 women from five European countries,  was performed to estimate the diagnostic performance of the CINtec® PLUS* cytology test in screening for cervical precancers compared to more traditional screening methods like Pap cytology. The study assessed whether the test, which uses two biomarkers, p16 and Ki-67, that are indicative of oncogenic (cancer-causing) human papillomavirus (HPV) infections, provides both high sensitivity and specificity for high-grade precancerous cervical lesions. The results showed that when compared to Pap cytology testing, the CINtec PLUS cytology test was more effective than Pap cytology in detecting precancerous lesions.  Pap cytology had a sensitivity of 67.5% while the CINtec PLUS test had a sensitivity of 86.7%.

(Photo: http://photos.prnewswire.com/prnh/20131104/LA09354 )

"The results of PALMS confirms data from previous studies which have shown that incorporating the CINtec PLUS test in cervical cancer screening programs can provide real benefit to both clinicians and their patients," says Dr. Christine Bergeron, Laboratoire Cerba, Cergy, Paris, France, PALMS study investigator and publication co-author.  "In young women, where HPV infection rates may be high, the CINtec PLUS test could be very useful to identify those women with clinically significant precancers who may be missed by the lower sensitivity Pap test.  In older women, combining the CINtec PLUS test with HPV DNA testing would make a lot of sense."

More than 500,000 new cases of cervical cancer are diagnosed each year worldwide. 2 Disappointingly, the average five-year survival rate of patients is only around 50%. 2 HPV infections are common and cause virtually all cervical cancer. 2  However, only those women with persistent HPV infections and who have developed high-grade precancerous cervical disease should be treated. The CINtec PLUS cytology test was developed to help identify those HPV infections that may lead to cancer and distinguish them from those that will not.

The authors (Safaeian and Sherman) of an editorial published along with the PALMS study results write that dual biomarker screening could have a role in primary screening, especially in younger women. They also conclude that the dual assay could serve as a triage for positive HPV tests and could dramatically decrease patient referrals to colposcopy and other invasive and costly procedures unnecessarily.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,478.95 +79.28 0.48%
S&P 500 1,923.20 +19.19 1.01%
NASDAQ 4,370.7770 +54.7030 1.27%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs